IMMIX BIOPHARMA INC

Immix Biopharma shares fell 4.49% to $8.35, reflecting market volatility and pipeline uncertainty in this clinical‑stage biopharma focused on tissue‑specific cancer and IBD therapies.

Immix Biopharma (IMMX) jumps 8.39% to $8.91 amid new data, trading below its 200‑day SMA with a wide 52‑week range—ideal for investors tracking breakthrough biopharma moves.